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Deok-Hwan Yang,1 Won Seog Kim,2 Seok Jin Kim,3 Sung Hwa Bae,4 Sung Hyun Kim,5
In Ho Kim,6 Sung Soo Yoon,6 Yeung-Chul Mun,7 Ho-Jin Shin,8 Yee Soo Chae,9
Jae-Yong Kwak,10 Hawk Kim,11 Min Kyoung Kim,12 Jin Seok Kim,13 Jong Ho Won,14
Je-Jung Lee,1 Cheol Won Suh15High-dose chemotherapy followed by autologous stem cell transplantation (HDT/ASCT) offers a rescue
option for T cell lymphoma patients with poor prognosis. However, the effectiveness of HDT/ASCT in
patients with various peripheral T cell subtypes, optimal transplant timing, and the prognostic factors that
predict better outcomes, have not been identified. We retrospectively investigated the clinical outcomes
and prognostic factors for HDT/ASCT in 64 Korean patients with peripheral T cell lymphoma, unspecified
(PTCL-U) between March 1995 and February 2007. The median age at transplantation was 44 years (range:
15-63 years). According to the age-adjusted International Prognostic Index (a-IPI) and the prognostic index of
PTCL (PIT), 8 patients (12.5%) were in the high-risk group and 16 (26.6%) had the 2-3 PIT factors, respec-
tively. After a median follow-up of 29.7 months, the 3-year overall survival (OS) and progression-free survival
(PFS) rates were 53.0% 6 7.5% and 44.3% 6 7.0%, respectively. Univariate analysis showed that poor
performance status, high lactate dehydrogenase (LDH) levels, high a-IPI score, high PIT classes, failure to
achieve complete response (CR) at transplantation, and nonfrontline transplantation were associated with
poor OS. Multivariate analysis showed that failure to achieve CR at transplantation (hazard ratio [HR]
2.23; 95% confidence interval [CI] 1.78-7.93) and 2-3 PIT factors (HR 3.76; 95% CI 1.02-5.42) were indepen-
dent prognostic factors for OS. Failure to achieve CR at transplantation and high PITare negative predictable
factors for survival following HDT/ASCT in patients with PTCL-U.
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Table 1. Patient Pretransplant Characteristics
N %
Gender (male/female) 45/19 70.3/29.7
Age, median (years) 44 (15-63)
Performance status
0-1 52 81.3
2-3 12 18.8
Stage at diagnosis
Stage I/II 3/16 4.7/25.0
Stage III/IV 19/26 29.7/40.6
B symptoms 22 34.4
LDH Normal 39 60.9
High 25 39.1
Age-adjusted IPI at diagnosis
Low 15 23.4
Low-intermediate 21 32.8
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derstanding of the pathophysiology and optimal treat-
ment of T cell lymphomas has been limited by the
relative rarity of the condition and histologic subtype
heterogeneity, making the determination of the natural
course and the prognostic factors relative to each T
cell lymphoma subtype difficult. The International Pe-
ripheral T Cell Lymphoma Project has recently
reported that patients with anaplastic large cell lym-
phoma (ALCL), whether positive or negative for ana-
plastic lymphoma kinase (ALK), have superior
survival outcomes compared with patients with periph-
eral T cell lymphomas, unspecified (PTCL-U) [5]. To
better define the clinical outcome of PTCL, evaluation
of the prognostic markers and treatment strategies for
each PTCL subtype should be evaluated.
PTCL-U is the most common subtype of PTCL,
and often presents in an advanced stage at the time
of diagnosis, and with an aggressive clinical course
despite treatment [6,7]. The 5-year survival rate of
patients with PTCL-U ranges between 25% and
45% [8-10], which make this T cell lymphoma subtype
a risk factor per se, independent of other risk factors
such as those shown by the International Prognostic
Index (IPI) [6,11]. Although IPI has been reported to
be useful in predicting the clinical outcome of
PTCL, the impact of IPI on specific PTCL subtypes
has not been determined [12,13]. In addition, a new
prognostic model for PTCL has been suggested, com-
posed of four independent variables: age, lactate dehy-
drogenase (LDH), performance status, and bone
marrow involvement [14].
High-dose chemotherapy followed by autologous
stem cell transplantation (HDT/ASCT) offers a rescue
option for PTCL patients with poor prognosis
[10,15,16]. However, the effectiveness of ASCT in
patients with various PTCL subtypes, the optimal
timing of transplantation, and the prognostic factors
predicting better outcome, have not been determined.
We therefore retrospectively assessed the clinical out-
comes of and determined the prognostic factors for
HDT/ASCT in 64 Korean patients with PTCL-U.High-intermediate 20 31.3
High 8 12.5
PIT at diagnosis
0 factor 30 46.9
1 factor 18 26.6
2-3 factors 16 26.6
Primary chemotherapy
CHOP 43 67.2
CHOP and etoposide± gemcitabine 14 21.9
CHOP and alemtuzumab 1 1.6
IMVP-16 or promace cytabom 6 9.5
Response after
primary chemotherapy
CR/PR 33/18 51.6/28.1
SD/PD 4/9 6.3/14.1
Radiation therapy 12 18.8
IPI indicates International Prognostic Index; PIT, prognostic index of
PTCL; LDH, lactate dehydrogenase; CR, complete remission; PR, partial
remission; SD, stable disease; PD, progressive disease;PATIENTS AND METHODS
Patient Eligibility
Clinical outcomes following HDT/ASCT were
assessed in patients with PTCL-U who were treated
at 14 Korean institutions between March 1995 and
February 2007. PTCL-U was histologically diagnosed
according to the REAL classification [17], which was
later modified to conform with the WHO classifica-
tion. All biopsy specimens with unconfirmed histo-
pathologic features were referred to experienced
hematopathologists, and the immunohistochemical
and molecular characteristics were assessed duringcentral review committee. The study enrolled 64
patients aged#65 years with adequate cardiac, pulmo-
nary, hepatic, and renal function before transplanta-
tion. The patients were staged according to the Ann
Arbor staging system and evaluated using standard
procedures, including physical, laboratory, radiologic,
and bone marrow examinations. The same methods
were used to evaluate therapeutic responses to primary
or salvage chemotherapy, and to HDT/ASCT. Patient
prognosis was determined according to the age-
adjusted International Prognostic Index (a-IPI) and
the Prognostic Index for PTCL (PIT) (Table 1).
Frontline HDT/ASCT was permitted in patients
with bulky ($10 cm) or advanced (stage III or IV)
disease, or those who had high-risk a-IPI ($2) or 3-4
PIT factors at diagnosis.Response Criteria
Responses to primary chemotherapy, salvage che-
motherapy, and HDT/ASCT were assessed according
to the International Workshop Criteria (IWC) [18].
First complete response (CR1) and first partial
response (PR1) were defined as having achieved a CR
and PR after primary chemotherapy. Chemosensitive
relapsed or refractory CR (CR2) and PR (PR2) were
defined as CR and PR after salvage chemotherapy.
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response to treatment or progression during or within
1 month after completing treatment. Response to
HDT/ASCT was assessed 2 or 3 months after trans-
plantation. Imaging modalities were used to restage
tumors every 3 months for the first 2 years after
ASCT, every 6 months for the next 2 years, and then
yearly or whenever clinically indicated.Pretransplantation and Transplantation
Protocols
Most patients received an anthracycline-based
chemotherapy regimen as first-line treatment, except
for 6 patients who received IMEP (ifosfamide, metho-
trexate, etoposide, and prednisolone) or promace cyta-
bom chemotherapy. Patients with relapsed or
refractorydiseasewere treated with a salvagechemother-
apy regimen, including DHAP (dexamethasone, ara-C,
cisplatin), ICE (ifosfamide, carboplatin, etoposide),
ESHAP (etoposide, ara-C, cisplatin, methylpredniso-
lone), or dose-adjusted EPOCH (cyclophosphamide,
etoposide, vincristine, doxorubicin, and methylprednis-
olone). Thirty-one patients (48.4%) were mobilized
with cyclophosphamide (4 g/m2) plus granulocyte
colony-stimulating factor (G-CSF) (10mg/kg/day), 9 pa-
tients were mobilized with salvage chemotherapy plus
G-CSF, and 19 patients (29.7%) were mobilized with
G-CSF alone. The median number of stem cell collec-
tions was 2 (range: 1-11). The stem cell source in all cases
was the peripheral blood.Statistical Analysis
Descriptive statistics are summarized as frequency
counts and percentages for categoric variables and as
medians and range for continuous variables. Progres-
sion-free survival (PFS) was calculated from the date of
ASCT to the first recording of disease relapse, progres-
sion, or death from any cause. Patients whose disease did
not progress were censored using the date when they
were last known to show no progression. Overall
survival (OS) was defined as the time from transplanta-
tion to the date of last follow-up or death from any cause.
The distribution of patients in OS and PFS was esti-
mated using the Kaplan-Meier product-limit method
and compared by the log-rank test for the association be-
tween clinical prognostic factors and the probability of
treatment failure. Multivariate Cox’s proportional-
hazards models were used to analyze all factors found
to be significant during the univariate analysis. Trans-
plant-related mortality included all deaths within 60
days of transplantation without disease progression.
Two-tailed P-values\.05 were considered statistically
significant. All statistical analyses were performed using
SPSS statistical software, version 13.0 (SPSS, Inc.,
Chicago, IL).RESULTS
Pretransplantation Characteristics, Stem Cell
Collection, and Conditioning Regimens
The pretransplantation characteristics of the 64 in-
cluded patients are summarized in Table 1. Their
median age was 44 years (range: 15-63 years) and the
median time from diagnosis to transplantation was
10.5 months (range: 3.7-74.6 months). Forty-five
patients (70.3%) presented in advanced stages (III/
IV) and 22 (34.4%) had B symptoms. At diagnosis,
28 patients (43.8%) were classified as high risk accord-
ing to the a-IPI scoring system and 16 (26.6%) were
classified as high risk by the PIT. The overall response
rate to primary chemotherapy was 79.7%. There was
no significant difference in response rates between
patients treated with CHOP alone or CHOP-like
chemotherapy and those treated with another nonan-
thracycline-based chemotherapeutic regimen. Twelve
patients (18.7%) received a short course of chemother-
apy followed by involved field radiation therapy
(IFRT). Twenty-eight patients (43.8%) received
HDT/ASCT after primary chemotherapy, whereas
36 patients (56.2%) received 2 or more chemotherapy
regimens before transplantation. Sixteen patients
(25.0%) underwent HDT/ASCT while in CR1 and
12 (18.8%) while in PR1 after primary chemotherapy.
However, 5 patients (7.9%) were transplanted in CR2
and 25 (39.0%) in PR2 after salvage chemotherapy.
Overall, 21 patients (32.9%) achieved CR at transplan-
tation and 6 (9.4%) underwent HDT/ASCT when
their status was progressive or chemorefractory.
With a median number of 2 stem cell collections
(range: 1-11), an average of 6.0  106/kg CD341 cells
was infused. The hematologic recovery of granulo-
cytes (absolute neutrophil count [ANC] .500/mL)
and platelets (.20,000/mL) occurred at a median
time of 12 and 14 days, respectively. Conditioning reg-
imens varied between participating centers. Twenty-
five patients (39.1%) were conditioned with BCNU,
etoposide, cytarabine, and melphalan (BEAM), and
20 patients (31.3%) with busulfan, cyclophosphamide,
and etoposide (BuCyE). Only 3 patients (4.7%)
received total-body irradiation (TBI)-based condition-
ing (Table 2).
The transplant-related mortality (TRM) rate was
6.2%. Two patients died from veno-occlusive disease
and 2 from severe neutropenic infections.Posttransplantation Outcomes and Prognostic
Factors
After a median follow-up time of 29.7 months
(range: 6.5-155.7 months), 36 patients (56.2%) were
alive, whereas 25 (39.1%) had relapsed or progressed.
The 3-year OS and PFS rates were 53.0 6 7.5 % and
44.3 6 7.0 %, respectively (Figure 1). The similarity
Table 2. Clinical Parameters Associated with HDT/ASCT
Parameters N %
Disease status at ASCT
CR1/PR1 16/12 25.0/18.8
Chemosensitive relapsed/
refractory CR/PR
5/25 7.9/39.0
Progressive or refractory 6 9.4
Mobilization
G-CSF alone 19 29.7
Salvage chemotherapy and G-CSF 9 14.1
Cyclophosphamide and G-CSF 31 48.4
Other chemotherapy and G-CSF 5 7.8
Number of PBSCC, median 2 (1-11)
Infused CD34+ cell dose, median 6.0 (1.5-29.1)
$6.0  106/kg 37 57.8
<6.0  106/kg 27 42.2
Conditioning regimen
BEAM 25 39.1
BuCyE 20 31.3
BEAC 7 10.9
CyTBI 3 4.7
Others (BuCyMel or
salvage regimens)
9 14.1
Hematologic recovery after ASCT
Median days of ANC >500 D+12 (8-52)
Median days of PLT >20,000 D+14 (6-158)
Transplant-related mortality 4 6.2
Relapse after ASCT 25 39.1
Median time from diagnosis to ASCT 10.5 (3.7-74.6
months)
HDT/ASCT indicates high-dose chemotherapy followed by autologous
stem cell transplantation; ANC, absolute neutrophil count; G-CSF, gran-
ulocyte-colony stimulating factor; PBSCC, peripheral blood stem cell
count; CR, complete remission; PR, partial remission.
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of retreatment in patients who were not cured with
HDT/ASCT. Univariate analysis of factors influenc-
ing OS and PFS was presented in Table 3. We found
that poor OS was associated with high PS score, high
LDH, high a-IPI, and high PIT. Both a-IPI and PIT
showed good ability to predict OS and PFS. That is,
the 3-year OS rates were 64% and 64.8% in the low-
risk a-IPI and PIT 0 group, respectively; 48.1% and
49.0% in the low- to intermediate-risk a-IPI and PITFigure 1. Kaplan-Meier estimates of overall survival (OS) and progression-fr1 group, respectively; and 43.9% and 7.5% in the
high- to intermediate-risk a-IPI and PIT 2-3 groups,
respectively (Figure 2). We also found that disease sta-
tus at transplantation, achievement of CR at transplan-
tation, and frontline transplantation during CR1 or
PR1, all showed prognostic significance on OS. How-
ever, disease status at transplantation and transplant
timing did not have prognostic significance on PFS
(Figure 2). Other clinical factors, such as the dose of in-
fused CD341 cells, the conditioning regimen, and the
number of courses of salvage chemotherapy, had no
prognostic significance on either OS or PFS.
Multivariate analysis showed that failure to achieve
CR at transplantation (hazard ratio [HR] 2.23; 95%
confidence interval [CI] 1.78–7.93) and high PIT
scores of 2-3 (HR 3.76; 95% CI 1.02-5.43) were inde-
pendent prognostic factors for OS, and that high PIT
was an independent prognostic factor for PFS (HR
3.76; 95% CI 1.023-5.428).DISCUSSION
HDT/ASCT is widely accepted as the treatment of
choice for patients with chemosensitive relapsed or re-
fractory aggressive B cell lymphoma with long-term
PFS of 40% to 50% [19,20]. However, the role of
this procedure in PTCL is still unclear. Most retro-
spective studies have shown comparable outcomes of
HDT/ASCT in cases of relapsed or refractory
PTCL [21-25]. However, these studies included het-
erogeneous populations with varying IPI or PIT
scores, various subtypes of PTCL, and different dis-
ease status at transplantation, making determination
of clinical application and role of HDT/ASCT some-
what ambiguous.
In this study, we retrospectively evaluated the clin-
ical outcome of transplantation in patients with
PTCL-U. The 3-year OS and PFS rates were 53%ee survival (PFS) in 64 patients with PTCL-U who received HDT/ASCT.
Table 3. Univariate analysis of prognostic factors associated with overall survival (OS) and progression-free survival (PFS)
N 3-yr OS (95% CI) P N 3-yr PFS (95% CI) P
PS
0 - 1 52 52.9 ± 7.9 0.002 52 56.7 ± 8.1 0.124
2 – 4 12 9.0 ± 8.9 12 40.9 ± 16.3
LDH
Normal 39 57.5 ± 9.1 0.016 39 67.0 ± 8.8 0.012
High 25 24.2 ± 9.6 25 34.3 ± 11.3
Stage
I – II 19 54.7 ± 12.0 0.235 19 62.1 ± 12.6 0.602
III – IV 45 39.4 ± 8.5 45 49.1 ± 9.2
BM
Involved 14 11.5 ± 10.5 0.023 14 35.0 ± 15.4 0.156
Not involved 50 52.1 ± 8.0 50 57.7 ± 8.3
B symptom
Yes 22 29.2 ± 10.2 0.237 22 39.0 ± 11.8 0.245
No 42 56.6 ± 8.6 42 63.2 ± 8.7
Age-adjusted IPI
Low 15 66.5 ± 14.0% 0.039 15 64.0 ± 13.1 0.014
Low-intermediate 21 60.3 ± 12.0% 21 48.1 ± 14.6
High-intermediate 20 53.3 ± 13.6% 20 43.9 ± 12.3
High 8 Not reached 8 Not reached
PIT
0 30 71.7 ± 9.2 0.004 30 64.8 ± 9.9 0.001
1 18 57.3 ± 14.2 18 49.0 ± 13.3
2 - 3 16 20.8 ± 12.4 16 7.5 ± 6.7
Disease status at transplant
CR 21 71.8 ± 11.0 0.001 21 53.1 ± 12.5 0.263
PR 37 42.6 ± 8.6 37 55.1 ± 9.5
Progressive/refractory 6 Not reached 6 Not reached
Transplant timing
Frontline 28 60.0 ± 9.9 0.047 28 61.7 ± 10.3 0.188
Non-frontline 36 32.6 ± 9.4 36 46.3 ± 10.4
IPI indicates International Prognostic Index; CR, complete remission; PR, partial remission; PIT, prognostic index of PTCL; BM, bone marrow; LDH,
lactate dehydrogenase; PS, performance status.
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superior to those of previous studies [23,26-28]. At
a median follow-up time of 29.7 months, 39.1% of
the patients had relapsed and 56.2% were alive without
disease. When we compared the survival outcome of
our patients with outcomes seen in previous studies,
which included conventional chemotherapy treatment
or stem cell transplantation for PTCL-U, we found
that patients with low a-IPI or PIT scores had more
favorable prognoses after HDT/ASCT. However,
HDT/ASCT showed no benefit in patients with high
a-IPI or PIT (Table 4).
Although both a-IPI and PIT were good prognos-
tic indices in patients with PTCL-U who underwent
transplantation, PIT had better discriminatory power
for predicting OS and PFS in subgroup analysis. After
excluding the age factor of PIT (because 93.7% of
transplanted patients were \60 years old), 2 of the
remaining 3 factors were shared with a-IPI. Thus,
BM involvement could play an important role in creat-
ing a prognostic difference between a-IPI and PIT.
Patients with BM involvement consisted mainly of
those in the PIT 2-3 group (71.4%), whereas only
14.3% were classified into the high-risk group of a-IPI.
In a recent study of the long-term clinical out-
comes of HDT/ASCT in patients with heterogeneous
subtypes of PTCL, disease status at transplantationwas the major factor predicting clinical outcome
[29]. The 5-year PFS and OS rates for patients in
CR1/PR1 groups were 51% and 76%, respectively,
decreasing to 12% and 40%, respectively, for patients
in CR2/PR2. We observed similar results for HDT/
ASCT in patients with PTCL-U. The 3-year OS
rate for patients who achieved CR (n5 21), regardless
of transplant timing, was 71.8%. We found, however,
that 3-year OS rates differed significantly in patients
undergoing transplantation in CR1/PR1 (60%) and
those undergoing transplantation in a salvage setting
(37.7%). However, the 3-year OS rate for patients in
CR2 was 70.9%, compared with 50% for those in
PR1. Consequently, the achievement of CR at the
time of transplantation was a more significant factor
for predicting survival than was transplant timing.
Despite the limitations of retrospective analyses,
we found that HDT/ASCT in PTCL-U played
a less significant role in determining clinical outcome
in patients with adverse prognostic factors. Several
small studies have assessed the feasibility and long-
term survival of myeloablative or nonmyeloablative
SCT as salvage therapy in patients who were not che-
mosensitive or who displayed both adverse factors [30-
33]. Allogeneic SCT in patients with PTCL can give
rise to graft-versus-lymphoma (GVL) effects, which
may improve the therapeutic outcomes, but may also
Figure 2. Kaplan-Meier estimates of overall survival (OS) and progression-free survival (PFS) according to prognostic factors. (A) Age-adjusted IPI, (B)
prognostic index for PTCL-U, (C) disease status at transplantation, and (D) transplant timing.
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Table 4. Comparison of survival outcomes of PTCL-U with those of previous studies
In this study (after HDT/ASCT) Gallamini et al. (14) The International T-cell lymphoma project. (5)
Actuarial 5-year OS 5-year OS 5-year OS
International Prognostic index
Low 66.5% 58.9% 52%
Low-intermediate 60.3% 45.6% 33%
High-intermediate 43.9% 39.7% 16%
High Not reached 18.3% 13%
Prognostic index of PTCL
0 factor 71.7% 62.3% Nearly 50%
1 factor 51.7% 52.9% Nearly 30%
2 factors 20.8% 38.8% Nearly 20%
3 or 4 factors Not reached 18.3% Nearly 10%
OS indicates overall survival.
124 Biol Blood Marrow Transplant 15:118-125, 2009D.-H. Yang et al.be accompanied by high nonrelapse mortality (NRM)
after a myeloablative regimen and high relapse rate af-
ter nonmyeloablative conditioning. Outcomes in 17
patients with relapsed PTCL who received salvage
chemotherapy followed by reduced-intensity alloge-
neic SCT were improved, with estimated 3-year OS
and PFS rates of 81% and 64%, respectively, suggest-
ing that the graft-versus-T lymphoma effect may have
been responsible [34].
In conclusion, we have shown here that HDT/
ASCT was effective in patients with PTCL-U who
achieved CR at transplantation, regardless of trans-
plant timing. PIT reliably predicted the clinical out-
come of ASCT. However, HDT/ASCT was less
useful for those with high a-IPI or PIT scores. These
patients may achieve CR using a new combination
therapy regimen, following which intensified consoli-
dation using autologous or allogeneic SCT should be
considered.
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